Skip to main content

Table 2 AUROC of BCL-2 dependence following ibrutinib treatment for the prediction of treatment response and outcome

From: BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia

IN VIVO IBRUTINIB

FEATURE

AUROC (VALUE)

AUROC

(SD)

TREATMENT TIMEPOINT

RESPONSE (AREA)

PUMA (1 μM)

0.827

0.127

Post FCR

MRD PB

ABT199 (0.1 μM)

0.779

0.171

Post FCR

MRD PB

BAD (1 μM)

0.778

0.125

Best Response

MRD PB

ABT199 (0.1 μM)

0.774

0.130

Best Response

MRD BM

ABT199 (1 μM)

0.758

0.149

Post FCR

MRD PB

  1. Post FCR: End of combination therapy
  2. MRD PB: Minimal Residue Disease Peripheral Blood
  3. MRD BM: Minimal Residue Disease Bone Marrow
Back to article page

Molecular Cancer

ISSN: 1476-4598